RxDoctor Payments Data

Karla Hess

Family · Firth, IDNPI 1306325584

Payments from drug & device makers

$2,266in general payments, 2019–2025

Across 127 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$652
  • AbbVie$627
  • GSK$210
  • Novartis$189
  • Lilly USA, LLC$125
  • AstraZeneca$116
  • plus $347 from 7 others

What the payments were for

  • Food & beverage$2,266100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)37$652
AbbVie32$627
GSK13$210
Novartis10$189
Lilly USA, LLC7$125
AstraZeneca7$116
Johnson & Johnson(2 entities)6$89
Pfizer5$76
Astellas Pharma US Inc2$69
Novo Nordisk4$54
Bayer2$32
Boston Scientific1$19
Genentech USA, Inc.1$6

How this compares

$2,266 in reported general payments places this provider in the 85th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$14,808
Medicare patients
65
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$28,581
MounjaroTirzepatide22$26,639
Desmopressin Acetate12$2,039
Levothyroxine Sodium127$1,150
Gabapentin30$1,125
Duloxetine Hcl20$879
Bupropion XlBupropion Hcl17$404
Omeprazole59$401
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine11$371
Atorvastatin Calcium75$366
Hydroxychloroquine Sulfate14$248
Metformin Hcl ErMetformin Hcl45$244
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$244
Lisinopril76$244
Losartan Potassium28$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$54$28,58121 claims
Lilly USA, LLCMounjaro$125$26,63922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Idaho.

Other family in Firth

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →